Red Light Holland (TRIP) Q4 2025 earnings summary

Executive summary

• Fiscal year ended March 31, 2025, saw revenue growth to $4.944 million, up 4.05% year-over-year, despite global headwinds and sector challenges.

• Adjusted EBITDA loss reduced by 23.54% to $2.532 million, reflecting disciplined cost management and strategic exits from unprofitable businesses.

• Nearly all operating subsidiaries were cash positive, and the company maintained a strong cash balance of $12.838 million.

• Strategic focus shifted to efficient operations, functional mushroom products, and innovation in both product and digital finance.

• Achieved global milestones in psilocybin R&D, including the first legal shipment to a U.S. FDA/DEA-registered lab.

Financial highlights

• Revenue reached $4.944 million, a 4.05% increase year-over-year, driven by a focus on higher-margin products.

• Gross profit was $1.913 million, slightly down from $2 million the previous year, due to product mix changes.

• Adjusted EBITDA loss improved to $2.532 million from $3.3 million, a 23.54% reduction.

• Cash position at year-end was $12.838 million, down from $14.4 million, mainly due to investments in product development and strategic initiatives.

• Total assets closed at $21.221 million, down from $24.1 million, reflecting non-recurring adjustments and write-downs.

Outlook and guidance

• Focus remains on controlled growth, profitability, and capital preservation.

• Management emphasizes fiscal responsibility, innovation, and readiness for regulatory changes in psychedelics.

• Plans to expand functional mushroom gummies and leverage retail partnerships for broader distribution.

• Continued advocacy for regulatory change and market access in psychedelics, with ongoing R&D and international partnerships.

• Exploring sale of AEM Ontario farm to consolidate capital and support global expansion.